Access

Business

Nature 438, 913 (15 December 2005) | doi:10.1038/438913b; Published online 14 December 2005

In brief

British biotechnology company Astex Therapeutics last week announced a deal with Swiss drug giant Novartis that is potentially worth US$500 million. Under the agreement, Novartis will pay $25 million to secure the global licensing rights to Astex's anticancer drug AT9311.